{
    "xml": "<topic id=\"PHP81542\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/rhophylac\" basename=\"rhophylac\" title=\"Rhophylac\">\n<title>Rhophylac<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP82394\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/clinical-medicinal-product-information/rhophylac\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To rhesus-negative woman for prevention of Rh0(D) sensitisation, following birth of rhesus-positive infant</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Females of childbearing potential</p>\n<p>1000&#8211;1500&#8239;units, dose to administered immediately or within 72 hours; for large transplacental bleed, extra 100&#8239;units per mL fetal red cells (preferably by intravenous injection), intravenous route recommended for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks' gestation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Females of childbearing potential</p>\n<p>1000&#8239;units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Females of childbearing potential</p>\n<p>1500&#8239;units, dose to be given between weeks 28&#8211;30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To rhesus-negative woman for prevention of Rh0(D) sensitisation, following Rh0(D) incompatible blood transfusion</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Females of childbearing potential</p>\n<p>50&#8239;units/mL, dose per mL of transfused rhesus-positive blood, alternatively 100&#8239;units/mL, dose per mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81542",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/rhophylac",
    "basename": "rhophylac",
    "title": "Rhophylac",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following birth of rhesus-positive infant",
                        "html": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following birth of rhesus-positive infant"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By intramuscular injection or by intravenous injection",
                    "html": "By intramuscular injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1000&#8211;1500 units, dose to administered immediately or within 72 hours; for large transplacental bleed, extra 100 units per mL fetal red cells (preferably by intravenous injection), intravenous route recommended for patients with bleeding disorders.",
                        "html": "<p>1000&#8211;1500&#8239;units, dose to administered immediately or within 72 hours; for large transplacental bleed, extra 100&#8239;units per mL fetal red cells (preferably by intravenous injection), intravenous route recommended for patients with bleeding disorders.</p>",
                        "ageGroup": "females of childbearing potential"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks' gestation",
                        "html": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks' gestation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By intramuscular injection or by intravenous injection",
                    "html": "By intramuscular injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1000 units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation.",
                        "html": "<p>1000&#8239;units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation.</p>",
                        "ageGroup": "females of childbearing potential"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis",
                        "html": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, antenatal prophylaxis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By intramuscular injection or by intravenous injection",
                    "html": "By intramuscular injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1500 units, dose to be given between weeks 28&#8211;30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders.",
                        "html": "<p>1500&#8239;units, dose to be given between weeks 28&#8211;30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders.</p>",
                        "ageGroup": "females of childbearing potential"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following Rh0(D) incompatible blood transfusion",
                        "html": "To rhesus-negative woman for prevention of Rh0(D) sensitisation, following Rh0(D) incompatible blood transfusion"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "50 units/mL, dose per mL of transfused rhesus-positive blood, alternatively 100 units/mL, dose per mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders.",
                        "html": "<p>50&#8239;units/mL, dose per mL of transfused rhesus-positive blood, alternatively 100&#8239;units/mL, dose per mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders.</p>",
                        "ageGroup": "females of childbearing potential"
                    }
                ]
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}